Sophie G. Kellaway is a biomedical researcher specializing in cancer genomics and hematology, with a focus on the molecular mechanisms underlying blood cancers. Her research particularly investigates genetic mutations, including those affecting the RUNX1 gene, and their role in the development of leukemia. She is actively involved in scientific research and academic collaborations, contributing to peer-reviewed publications that explore gene regulation, stem cell biology, and cancer progression. Her work aims to improve the understanding of disease mechanisms and support the development of targeted therapies for hematological malignancies. Sophie Kellaway is affiliated with the University of Birmingham, where she works within the Institute of Cancer and Genomic Sciences. Through her research, she contributes to advancing knowledge in cancer biology and translational medicine.